Hemogenyx Pharmaceuticals Plc (LON:HEMO)

London flag London · Delayed Price · Currency is GBP · Price in GBX
183.25
-0.25 (-0.14%)
Apr 25, 2025, 4:35 PM BST
-71.55%
Market Cap 7.51M
Revenue (ttm) n/a
Net Income (ttm) -5.18M
Shares Out 4.09M
EPS (ttm) -1.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 27,944
Average Volume 21,568
Open 189.50
Previous Close 183.50
Day's Range 180.50 - 189.50
52-Week Range 160.00 - 1,200.00
Beta 3.47
RSI 42.43
Earnings Date Apr 25, 2025

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company’s lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hema... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 17
Stock Exchange London Stock Exchange
Ticker Symbol HEMO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.